Fig. 4: Silencing IFITM3 inhibits TGF-β-induced Smad-MAPK signaling pathway and PCa bone metastases in vivo. | Cell Death & Disease

Fig. 4: Silencing IFITM3 inhibits TGF-β-induced Smad-MAPK signaling pathway and PCa bone metastases in vivo.

From: IFITM3 promotes bone metastasis of prostate cancer cells by mediating activation of the TGF-β signaling pathway

Fig. 4

a, b GO and KEGG pathway analysis of microarray results after IFITM3 knockdown. c Western blotting was used to analyze protein expression changes of TGF-β Receptor, N-cadherin, and Smad4 with TGF-β (5 ng/mL) incubation for 24 h compared with the normal control. d Changes in metastasis-related molecules after knocking down IFITM3 with or without TGF-β (5 ng/mL) added by qPCR analysis. e Representative immunohistochemical images are presented about IFITM3 expression in PCa bone metastasis tissues. f Metastasis lesions were monitored by bioluminescence intensity in mice after 4 weeks tail vein injection of PC-3 cells

Back to article page